Group 1 - The first domestically developed nine-valent HPV vaccine, "Cecolin®9," has been approved for market release in China, breaking a long-standing foreign monopoly on the market [2][6] - The incidence and mortality rates of cervical cancer in China have been rising over the past 30 years, with a notable trend towards younger demographics [3] - The nine-valent HPV vaccine provides over 98% protection against persistent infections from HPV types not covered by the bivalent vaccine, with a 100% protection rate against cervical infections [4] Group 2 - The development of the nine-valent HPV vaccine took 18 years, involving significant breakthroughs in technology and extensive clinical trials with over 11,000 participants [4] - The approval of the nine-valent HPV vaccine marks a significant advancement in China's biopharmaceutical sector, establishing the country as the second in the world, after the United States, capable of independently supplying high-cost HPV vaccines [6] - The World Health Organization's global strategy to accelerate the elimination of cervical cancer aligns with China's action plan, which emphasizes promoting HPV vaccination as a key objective [6]